The Alliance for Artificial Intelligence in Healthcare (AAIH)

Earlier this month the EU released the European Union Artificial Intelligence Act (The Act). #AAIHmembers Paul Howard, PhD, Senior Director of Amicus Therapeutics, Elaine H., Executive Director of the The Alliance for Artificial Intelligence in Healthcare (AAIH), Mustaqhusain Kazi Global Head of Informatics Strategy and Digital Innovation at Roche, Rafael Rosengarten Co-Founder and CEO of Genialis and James Zanewicz, JD, LLM, RTTP, Chief Business Officer at Tulane University School of Medicine, authored a response of behalf of #AAIH to the provisional agreement. This article provides valuable insights into several key aspects: the presence of bias in healthcare AI, the existing solutions addressed by the General Data Protection Regulation (GDPR), the dedication to ethically implementing AI, and the crucial role of human oversight in enhancing AI literacy. #aiinhealthcare #AI #regulation #GDPR #EU #theAct Read more in the full article here

As we celebrate the achievements of remarkable women in AI this #InternationalWomensMonth, the AAIH is excited to feature Barbara Fiacco, Intellectual Property Department and Patent, Trade Secrets, and Related Rights Litigation Co- Chair at Foley Hoag LLP! Barbara recently participated in the 10th Annual Naples Roundtable Conference, where she took part in a thought-provoking panel discussion on the evolving role of artificial intelligence in patent litigation. The panel explored critical questions surrounding AI’s impact on claim construction, prior art generation, and how courts might integrate generative AI tools in patent case resolutions. The Naples Roundtable Conference brings together leading voices in intellectual property law to examine pressing issues facing the U.S. patent system, and Barbara’s expertise and leadership make her a key figure in these important discussions.

Exciting upcoming event for this week’s #WhatsUpWednesday! Join Rafael Rosengarten, AAIH Board Member and CEO of Genialis, for a fireside chat on Harnessing the Power of AI to Transform the Diagnosis and Treatment of Cancer. AI is revolutionizing the way we approach cancer, but how is it actually being applied in real-world healthcare settings? What challenges are we facing, and what incredible opportunities lie ahead? Rafael will share valuable insights on the intersection of AI and oncology! See details below!

Continuing our celebration of #InternationalWomensMonth, we are proud to highlight the incredible women in the AAIH community! Today, we are featuring Helen Z. from Altis Labs! At Altis Labs, Helen is at the forefront of transforming oncology trials with innovative AI models that predict long-term efficacy of new drugs. These AI models are trained on over 200 million images, integrating longitudinal clinical context and survival outcomes. The result? More accurate predictions of patient outcomes, beyond simple treatment response or disease progression, enabling clinical trial sponsors to make better-informed R&D decisions while speeding up time to market. In her pivotal role, Helen drives the go-to-market strategy alongside Altis Labs CEO, while also leading the finance and operations teams. Looking to the future, Helen believes that in the next 5-10 years, AI will revolutionize clinical research. By enabling faster, smaller, and more successful clinical trials, AI will help patients access more effective treatments sooner. It will also empower clinicians with deeper insights into patient responses, enhancing care decisions. Helen’s vision and leadership are shaping the future of healthcare, and we are excited to see where it leads! #AIInHealthcare #WomenLeadership #AI #Oncology #ClinicalResearch

The Alliance for Artificial Intelligence in Healthcare (AAIH) is excited to celebrate a remarkable achievement during #InternationalWomensMonth, as AAIH Secretary and Envisagenics CEO, Maria Luisa Pineda, PhD., has been named an honoree on Inc. Magazine's 2025 #FemaleFounders500 list! This prestigious recognition highlights the most inspiring women in business, and Maria's dedication to advancing AI-driven drug discovery and fostering innovation in life sciences makes her a true leader in the field!

The Alliance for Artificial Intelligence in Healthcare (AAIH) is looking forward to attending #BIOEuropeSpring, March 17–19, 2025. Let's propel the new wave of biotech innovation together! If you are attending, let us know! We would love to meet you!

Excited about the future of health and medicine? Join Daniel Kraft, MD at NextMed Health in San Diego, March 30th - April 2nd 2025! This event is a must-attend for anyone passionate about innovation in healthcare, and AAIH members can even take advantage of an exclusive VIP discount code! Don’t miss out—see you there!

The Alliance for Artificial Intelligence in Healthcare (AAIH)?is proud to highlight?DeciBio's #InternationalWomensDay event, hosted in partnership with?Myriad Genetics?last week in South San Francisco. This gathering brought together over?100 women?from across the life sciences and biotech industries for an evening dedicated to advancing women into decision-making roles. Among the speakers was?Megan Nacar,?AAIH member?and?Vice President of Commercial at DeciBio, who shared her personal journey into board service. She discussed her recent appointment as a?Board Advisor for Helio Genomics, a company leveraging?artificial intelligence and next-generation sequencing (NGS) to enhance early cancer detection, particularly for hepatocellular carcinoma (HCC)—one of the most prevalent and deadly forms of liver cancer. Megan’s story underscored a key theme of the night:?women belong at the table where industry-shaping decisions are made. The event provided a platform for women across all career stages to engage in meaningful discussions, build connections, and gain insight into how they can step into leadership and governance roles. The AAIH celebrates initiatives like this that align with our mission to foster diversity and inclusion in AI-driven healthcare innovation. When women’s voices are amplified in biotech and AI, we move closer to a future where technology and medicine serve?everyone?equitably. To learn more about DeciBio’s commitment to elevating women in leadership, visit DeciBio’s LinkedIn page, or follow along with the AAIH for updates on how we’re supporting diversity in AI-driven healthcare!

In honor of #InternationalWomensMonth, The Alliance for Artificial Intelligence in Healthcare (AAIH) is excited to spotlight the remarkable women who are making significant contributions to the field of AI every day! Today the AAIH is proud to feature Michelle Chen from Insilico Medicine! As the Chief Business Officer at Insilico Medicine, Michelle leads the company business strategies, revenue growth, and external partnerships.?Insilico Medicine is a?pioneer?in AI powered drug discovery and development, and were one of the first to apply Generative AI for small molecule design in the industry.??Much of the ground work they laid out years ago to build Pharma.AI platforms have come to fruition and yielded promising drug candidates, including multiple assets in Phase I and Phase II clinical?development in oncology, immunology and fibrosis. What excites Michelle the most about being in this industry is the transformation power of AI in drug discovery and potential drug development.?"At Insilico, we have witnessed the significant increase in target and drug discovery efficiency, shortening of preclinical development timeline at a small fraction of traditional cost with our own pipeline, as well as our partners' programs, with the help of AI. I am looking forward to more examples of AI impact on clinical development & drug?approvals in the near future.?We want to deliver medicine faster, cheaper, and more precisely for patients globally."

The Alliance for Artificial Intelligence in Healthcare (AAIH) is pleased to introduce our #StudentSpotlight featuring Abraham Obianke, a 4th year medical student from Ambrose Alli University in Nigeria and a registered member of The Alliance for Artificial Intelligence in Healthcare (AAIH). Abraham Obianke recently collaborated with his colleagues on a research work, titled "Diagnostic accuracy of ECG smart chest patches versus PPG smartwatches for atrial fibrillation detection: a systematic review and meta-analysis", and it has been officially published in the reputable BMC Cardiovascular Disorders (Springer Nature)! As a medical student, during his clinical rotations in Cardiology, he witnessed how challenging it was to detect atrial fibrillation early, coupled with the shocking reality that heart disease remains the world’s leading cause of death claiming over 17.9 million lives each year according to the World Health Organization (WHO). This fueled his interest to contribute to research aimed at improving early heart risk detection for patients globally. This study investigates how wearable devices, such as smart chest patches and smartwatches, perform in detecting atrial fibrillation. He hopes that their findings in this work, makes it easier for people and healthcare providers to catch atrial fibrillation early, manage heart health better, and ultimately reduce the burden of heart disease worldwide; in line with the United Nations Sustainable Development Goal 3 (SDG 3) of good health and wellbeing for everyone at all ages. Read more about this study by visiting: https://lnkd.in/eueJMc-6 The AAIH is thrilled to have student members like Abraham, who is making remarkable strides in the field of AI!